ValuEngine upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a strong sell rating to a sell rating in a report published on Wednesday.
A number of other brokerages have also recently issued reports on NERV. BidaskClub upgraded Minerva Neurosciences from a sell rating to a hold rating in a research note on Tuesday, January 16th. Zacks Investment Research upgraded Minerva Neurosciences from a hold rating to a buy rating and set a $7.25 price objective for the company in a research note on Friday, March 16th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $12.75.
NASDAQ NERV opened at $6.80 on Wednesday. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $11.15.
A number of large investors have recently made changes to their positions in the business. Highland Capital Management LP raised its stake in Minerva Neurosciences by 11.5% during the fourth quarter. Highland Capital Management LP now owns 2,160,544 shares of the biopharmaceutical company’s stock valued at $13,072,000 after buying an additional 222,642 shares during the last quarter. Franklin Resources Inc. raised its stake in Minerva Neurosciences by 3.6% during the fourth quarter. Franklin Resources Inc. now owns 1,235,000 shares of the biopharmaceutical company’s stock valued at $7,472,000 after buying an additional 42,700 shares during the last quarter. Ascend Capital LLC raised its stake in Minerva Neurosciences by 4.8% during the fourth quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock valued at $4,957,000 after buying an additional 37,659 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Minerva Neurosciences by 24.0% during the fourth quarter. Sphera Funds Management LTD. now owns 775,000 shares of the biopharmaceutical company’s stock valued at $4,689,000 after buying an additional 150,000 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Minerva Neurosciences during the third quarter valued at $2,835,000. Institutional investors and hedge funds own 70.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3341197/minerva-neurosciences-nerv-upgraded-to-sell-at-valuengine.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.